Sudarshan Chemical Industries Limited announces an acquisition

The errata correction cannot be quantified from the cited disclosure: it does not reproduce the original investor-presentation figures or specify revised enterprise value, assumed debt, EBITDA, or transaction multiples. Therefore, the change in previously disclosed pro-forma leverage ratios cannot be calculated reliably.

The only directly relevant post-transaction figures disclosed are:

• Group net debt: Rs 755 Crores, including acquisition finance.
• Net debt-to-equity: 0.30x.

^[1]

What would change mechanically

• A correction to enterprise value alone would alter EV-based measures such as EV/EBITDA, but would not automatically change net debt/EBITDA leverage.
• A higher assumed debt would increase pro-forma net debt and therefore raise debt/EBITDA and net debt/equity.
• A lower corrected EBITDA would also raise leverage ratios, even if debt were unchanged.
• Conversely, lower debt or higher EBITDA would reduce the ratios.

Accordingly, the supported conclusion is that Sudarshan’s reported post-acquisition net debt position was Rs 755 Crores and net debt/equity was 0.30x, but the old-versus-corrected pro-forma leverage bridge remains undisclosed in the material cited here. Exact revised ratios require the errata and the original presentation figures, particularly assumed debt and the EBITDA denominator.

No material change in transferred assets or liabilities is indicated by the errata. The errata is described as correcting the counterparty name in the VP4 Frankfurt presentation, not revising the transaction perimeter, consideration, or assumed liabilities.^[2]

Cash inflow

The reported transaction remains a cash sale of Sudarshan’s entire 100% stake in VP4 Frankfurt GmbH for EUR 76.5 million.^[3] A separate report states that the EUR 76.5 million is payable upon completion.^[4] Accordingly, the expected gross cash inflow appears unchanged, subject to completion and any normal closing adjustments that are not disclosed in the retrieved material.

Impact on Heubach integration cost

The errata therefore does not, on the disclosed facts, reduce or increase the net cost of integrating the broader Heubach acquisition. The analytical bridge remains:

Net integration cash burden = Heubach integration and restructuring outflows − VP4 sale proceeds

Since no revised VP4 asset/liability scope or revised consideration is reported, the EUR 76.5 million proceeds should still be treated as the offset to those costs—not as evidence of a new reduction in liabilities assumed within Heubach.

The important unresolved issue is counterparty identity: the errata coverage refers to Mitsui & Co. as the corrected counterparty,^[2] while transaction reports describe the buyer as Celanese, including the 100% stake sale.^[3] That inconsistency warrants checking the company’s final errata or definitive transaction filing. It does not, by itself, demonstrate a change in assets, liabilities, cash proceeds, or integration economics.

No—based on the disclosed information, the errata does not indicate a change to either the completion timeline or the regulatory/closing conditions.

The transaction disclosure continues to state that completion of the VP4 Frankfurt GmbH sale is subject to fulfilment of the previously specified conditions precedent and customary closing conditions; it does not announce a revised completion date, new regulatory approval, amended outside date, or modified closing condition. ^[5] The underlying transaction remains the sale of 100% of VP4 Frankfurt to Celanese. ^[6]

Interpretation: the errata appears to be a clarification or correction to the announcement rather than a substantive amendment to the definitive agreements. Accordingly, the previously communicated timeline remains the applicable one, subject to the existing conditions precedent and customary closing mechanics.

The specific errata text and the operative clauses of the definitive agreements are not reproduced in the cited disclosure. Therefore, this conclusion is based on the absence of any disclosed change—not on an independent legal review of the amended wording.